Form 4: ADC Therapeutics CFO Reports Share Withholding for Tax

ADC Therapeutics' Chief Financial Officer, Jose Carmona, reported a disposition of 53,236 common shares for tax withholding related to restricted share unit vesting.

Summary

• Jose Carmona, Chief Financial Officer of ADC Therapeutics SA (ADCT), reported a transaction on December 6, 2025.
• The transaction involved the disposition of 53,236 common shares.
• These shares were withheld by the issuer to satisfy tax withholding obligations in connection with the vesting of previously granted restricted share units (RSUs).
• The shares were valued at a deemed price of $3.29 per share for tax purposes.
• Following this transaction, Jose Carmona directly beneficially owns 488,656 common shares.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction related to tax withholding for RSU vesting, which is a standard part of executive compensation and does not indicate a change in company fundamentals or management's view of the stock.

Positives

• The vesting of restricted share units (RSUs) indicates the fulfillment of compensation incentives for the Chief Financial Officer, aligning management interests with shareholder value over time.

Negatives

• A total of 53,236 common shares were disposed of by the Chief Financial Officer, reducing his direct beneficial ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The transaction is a routine administrative event related to executive compensation and is unlikely to have a significant direct impact on the company's share price or operational performance.

Key Dates

Recommendation

The filing details a routine insider transaction for tax withholding purposes related to RSU vesting. This administrative event does not provide new fundamental information about ADC Therapeutics' operational performance, financial health, or strategic direction to warrant a change in investment recommendation.

Keywords

ADC Therapeutics, ADCT, Jose Carmona, CFO, Form 4, Insider Transaction, Share Withholding, RSU Vesting, Executive Compensation